Life Science Investing SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025 17 October
Life Science Investing Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types 13 October
Life Science Investing SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration 13 October
